Several recent mergers and acquisitions in the biopharma industry have focused not only on key drug assets but also on retaining specialized teams, according to an April 15 article by BioSpace. The trend highlights how expertise within target organizations is becoming a central factor for buyers seeking growth and innovation.
The importance of workforce retention is evident as companies look beyond products to the knowledge and skills held by employees. In some cases, such as Gilead Sciences’ acquisition of Tubulis GmbH, the buyer plans to keep the acquired company’s team intact as a dedicated research and development unit.
Tubulis CEO Dominik Schumacher said, “We and Gilead believe our team is one of our greatest assets and was an important consideration as part of this transaction.” He added, “We strongly believe that Gilead saw not only the full potential and depth of our pipeline and technologies but also the expertise of our world-class team as a core asset.”
Other notable deals include Biogen’s $5.6 billion purchase of Apellis Pharmaceuticals. Biogen CEO Chris Viehbacher said that working with Apellis’ nephrology team would help accelerate the launch of new kidney disease treatments: “We just think that if the clinical trials work out for felzartamab as we hope, that we will have a running start into the launch, and we could actually potentially achieve peak sales faster than we would if we were just doing this on our own.”
AstraZeneca has also made strategic moves by acquiring Fusion Pharmaceuticals for $2.4 billion to add radioconjugate assets along with experienced staff in radiopharmaceuticals manufacturing. Fusion CEO John Valliant said at the time, “This acquisition combines Fusion’s expertise and capabilities in radioconjugates, including our industry-leading radiopharmaceutical R&D, pipeline, manufacturing and actinium-225 supply chain, with AstraZeneca’s leadership in small molecules and biologics engineering to develop novel radioconjugates.”
In rare diseases, AstraZeneca integrated Amolyt Pharma into its Alexion unit after a $1.06 billion deal. Alexion CEO Marc Dunoyer stated: “As leaders in rare disease, Alexion is uniquely positioned to drive the late-stage development and global commercialization of eneboparatide… We believe this program together with Amolyt’s talented team… will enable our expansion into rare endocrinology.” Amolyt CEO Thierry Abribat credited his staff for their continued efforts: “This award is first and foremost for the Amolyt Pharma team... The story will end when our drug candidates are available to patients internationally.”
The article also notes Vertex Pharmaceuticals’ acquisition of Alpine Immune Sciences for $4.9 billion centered around both product potential—povetacicept—and Alpine's protein engineering capabilities.
These examples suggest that future biopharma M&A activity may increasingly focus on securing talent alongside promising pipelines.
